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Abstract
The principle of dynamic liver function breath tests is founded on the administration of a 13C-labeled drug and subsequent 
monitoring of 13CO2 in the breath, quantified as time series delta over natural baseline 13CO2 (DOB) liberated from the drug 
during hepatic CYP-dependent detoxification. One confounding factor limiting the diagnostic value of such tests is that only 
a fraction of the liberated 13CO2 is immediately exhaled, while another fraction is taken up by body compartments from 
which it returns with delay to the plasma. The aims of this study were to establish a novel variant of the methacetin-based 
breath test LiMAx that allows to estimate and to eliminate the confounding effect of systemic 13CO2 distribution on the DOB 
curve and thus enables a more reliable assessment of the hepatic detoxification capacity compared with the conventional 
LiMAx test. We designed a new test variant (named "2DOB") consisting of two consecutive phases. Phase 1 is initiated by 
the intravenous administration of 13C-bicarbonate. Phase 2 starts about 30 min later with the intravenous administration of 
the 13C-labelled test drug. Using compartment modelling, the resulting 2-phasic DOB curve yields the rate constants for 
the irreversible elimination and the reversible exchange of plasma 13CO2 with body compartments (phase 1) and for the 
detoxification and exchange of the drug with body compartments (phase 2). We carried out the 2DOB test with the test drug 
13C-methacetin in 16 subjects with chronic liver pathologies and 22 normal subjects, who also underwent the conventional 
LiMAx test. Individual differences in the systemic  CO2 kinetics can lead to deviations up to a factor of 2 in the maximum 
of DOB curves (coefficient of variation CV ≈ 0.2) which, in particular, may hamper the discrimination between subjects 
with normal or mildly impaired detoxification capacities. The novel test revealed that a significant portion of the drug is not 
immediately metabolized, but transiently taken up into a storage compartment. Intriguingly, not only the hepatic detoxifica-
tion rate but also the storage capacity of the drug, turned out to be indicative for a normal liver function. We thus used both 
parameters to define a scoring function which yielded an excellent disease classification (AUC = 0.95) and a high correlation 
with the MELD score (RSpearman = 0.92). The novel test variant 2DOB promises a significant improvement in the assessment 
of impaired hepatic detoxification capacity. The suitability of the test for the reliable characterization of the natural history 
of chronic liver diseases (fatty liver—fibrosis—cirrhosis) has to be assessed in further studies.
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Introduction
The rationale of dynamic liver function tests consists in 
using the hepatic elimination rate of a properly chosen test 
compound as a measure for the overall ’hepatic functional 
mass’. Liver damage may include dysfunction of subcel-
lular organelles (e.g. endoplasmic reticulum and mitochon-
dria) as well as a reduction in the number of metabolically 
active hepatocytes, both processes affecting the CYP-
450-dependent detoxification rate of a test drug. Breath 
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tests, in particular, share the principle that a subject is 
administered an exogenous test compound (e.g. aminopy-
rine, galactose, phenylalanine or methacetin) in which the 
common 12C atom of a functional group has been replaced 
by the stable 13C isotope. In the liver, 13CO2 is enzymati-
cally cleaved from the functional group, typically by an 
enzyme of the CYP-450 family, enters the plasma and is 
then expired. As about 1% of the natural carbon atoms 
of our body compounds are present as the stable isotope 
13C, the abundance of the excess 13CO2 in the breath is 
quantified as delta-over-baseline (DOB) defined as rela-
tive concentration difference  ([13CO2]–[13CO2]baseline)/
[13CO2]baseline given in per mille (‰).
Breath tests are attractive for being less invasive, rela-
tively simple and having a high patient acceptance (Bon-
frate et al. 2015; Braden et al. 2007). Amongst the various 
substrates utilized to evaluate quantitative liver function, 
the 13C-methacetin breath test (MBT) has shown to be most 
promising (Buechter et al. 2018; Klatt et al. 1997). In its 
original design, the MBT is performed by oral administra-
tion of the test drug and subsequent measurement of the 
cumulative percentage of the administered dose of 13CO2 
recovered in the breath over time. Stravitz et al. (2015) 
reported that the oral MBT was superior to the MELD score 
in predicting the risk of cirrhotic complications and mortal-
ity in patients listed for liver transplantation. The oral 13C-
MBT was also successfully evaluated in the assessment of 
acute liver injury in a rat model (Zhu et al. 2014).
As individual differences in the intestinal uptake of the 
test drug may distort the test results, an improved variant 
of the MBT test (LiMAx test) has been developed at the 
Charite Berlin based on the intravenous administration of 
the drug and quasi-continuous monitoring of 13CO2 in the 
breath by means of an ultra-sensitive laser system (Stock-
mann et al. 2009). The LiMAx test has been successfully 
validated as a valuable non-invasive test in liver surgery 
for the pre- and postoperative assessment of organ function 
(Stockmann et al. 2009; Rubin et al. 2016) and for clas-
sifying the risk of cirrhotic complications and mortality 
in patients evaluated for liver transplantation (Jara et al. 
2015). Moreover, in a retrospective study encompassing 
102 patients with chronic liver disease who underwent a 
liver biopsy, the LiMAx test performed better than tran-
sient elastography (TE) and several serum biomarkers in 
detecting different stages of liver fibrosis and cirrhosis 
(Buechter et al. 2018). Nevertheless, the capability of the 
LiMAx test to reliably discriminate between a non-fibrotic 
(F0) and mildly-fibrotic (F1) liver was equally poor than 
observed with the oral version of the MBT (Dinesen et al. 
2008; Razlan et al. 2011). Therefore, to become accepted 
as a reliable clinical tool for the early detection of the 
onset loss of the liver’s functional parenchyma, it requires 
further improvement of the LiMAx test.
A detailed discussion of various confounding factors 
limiting the accuracy of the MBT is given in Gorowska-
Kowolik et al. (2017). In brief, there are two different cat-
egories of confounding factors diminishing the reliability of 
functional breath tests. First, even if the breath test was able 
to provide a precise information of the detoxification rate of 
the test drug, the utility of this parameter for the distinction 
between normal and diseased livers is restricted by several 
confounding factors such as the intake of medical drugs, 
smoking, aging or genetic variability which all may influ-
ence the expression level of the targeted metabolic pathway 
in the liver. Second, the kinetics of 13CO2 in the exhaled 
breath does not truly reflect the kinetics of enzymatic 13CO2 
formation in the liver. This is a consequence of the systemic 
distribution of 13CO2: A certain fraction of newly formed 
13CO2 is taken up into several body compartments from 
which it returns with delay to the plasma. Earlier studies 
on the systemic  CO2 dynamics in humans (Barstow et al. 
1989, 1990; Irving et al. 1983) revealed large variations in 
the rate of irreversible  CO2 elimination and  CO2 exchange 
with body compartments. Hence, depending on the size of 
the transiently trapped 13CO2 fraction in a specific subject, 
the DOB values may either over- or underestimate the actual 
hepatic formation rate of 13CO2. This fact is usually disre-
garded when equating the DOB value with the formation 
rate of 13CO2 in the liver.
To correct for the ‘CO2 bias’, we recently proposed a 
novel test variant (named “2DOB”) which is initialized with 
the injection of a standard dose of 13C-labeled bicarbonate 
(yielding information on the actual systemic  CO2 kinetics 
in the body of the individual) followed by injection of the 
13C-labeled test drug just as in the conventional breath test 
(Holzhutter et al. 2013). Computer simulations suggested 
that the predictive power of the proposed 2DOB breath test 
to reliably assess the CYP-specific hepatic detoxification 
activity should be significantly higher compared to the con-
ventional breath test. Here we report on a first preliminary 




16 patients with different types of liver pathologies (10 
males, 6 females) and 22 normal subjects (14 males, 8 
females) with no history or biochemical signs of liver dis-
ease, were enrolled in this study (for detailed information 
see Supplementary Table 1). In all except one patient, the 
diagnosis of the liver disease was histologically proven 
by histologic evaluation of either needle biopsy or surgi-
cal specimen. From healthy controls, a panel of laboratory 
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parameters (aminotransferases, γ-glutamyltransferase, coag-
ulation factors, bilirubin, alkaline phosphatase and albumin) 
was determined to exclude presence of a liver disease.
Experimental protocols
The study was carried out at the Department of Surgery, 
Charité Campus Mitte and Campus Virchow-Klinikum, 
Charité-Universitätsmedizin Berlin from July 2016 to Feb-
ruary 2018. The study protocol was approved by the ethics 
committee of the Charité-Universitätsmedizin Berlin and 
adhered to the latest version of the Declaration of Helsinki, 
and all the study participants provided written informed 
consent before enrollment. Every subject underwent two 
examination sessions, held on separate days.
2DOB test
To avoid isotopic effects from the food intake (Jonderko 
et al. 2008), the test was started after at least 3 h of fast-
ing. The subject was placed in a prone position. To analyze 
the whole breath continuously, a specifically designed face 
mask was used for easy collection of exhaled breath. The gas 
analyses were performed in real time at the bedside using the 
commercially available  FLIP® detection device (Humedics 
GmbH, Berlin, Germany) with a newly developed device 
for spectral analysis of the 13CO2 and 12CO2 amounts in the 
exhaled breath (Rubin et al. 2011, 2016). The intravenous 
injection of 13C-labeled bicarbonate (named 13C–B in the 
following) was performed after about 10 min when the DOB 
baseline has reached stable values. This injection resulted in 
a rapid increase of DOB values reaching a maximum after 
a few seconds. For the model-based computational analyses 
of the experimentally determined DOB data, the time point 
at which the DOB value of an individual patient has reached 
the maximum after injection of 13C–B was designated "0". 
Then, at time T = Tm ≈ 30 min after the injection of 13C–B, 
a dose of 2 mg/kg body weight of 13C-labeled methacetin 
(13C–M) was administered intravenously followed by a flush 
of 20 ml of isotonic saline solution. To keep the duration 
of the full test as short as possible, a time span of 30 min 
for phase 1 turned out to be sufficient for the unequivocal 
estimation of the parameters k−C, k+C and kR. Administration 
of 13C–M gave rise to a second increase of the DOB values 
followed by a more or less steep decline depending on the 
methacetin metabolizing capacity of the liver (see Fig. 2). 
Online sampling and analysis of the 13CO2/12CO2 ratio in 
the breath were performed with a time resolution of 25 s. To 
maintain a constant hemodynamic state, test subjects had to 
rest in a supine position throughout the test.
A compartment model (see below) was used to estimate 
from the experimentally determined time-dependent DOB 
data numerical values for the kinetic parameters characteriz-
ing the chemical conversion rate of 13C–M, the exchange of 
13C–B and 13C–M with body compartments and the irrevers-
ible elimination of 13C–B. These parameters were then tested 
for their ability to serve as classifiers for the discrimination 
between normal and diseased livers (see below).
LiMAx test
The LiMAx test is basically identical with the second phase 
of the 2DOB test. After calibration of the DOB baseline 
curve, the test is initiated with the intravenous injection of 
a dose of 2 mg/kg body weight of 13C–M. Blood samples 
were taken from eight subjects at six time points (= 60, 120, 
300, 600, 1200, 1800 s) after 13C–M injection for the deter-
mination of the plasma values of 13C–M. The classification 
score of the test, LiMAx, was introduced in (Stockmann 
et al. 2009) as
where  DOBmax is the maximum value of DOB, 
R(PDB) = 0.011237 is the baseline ratio 13CO2/12CO2 
according to the Pee Dee Belemnite standard (Craig 1957), 
P = 300 mmol/h/m2 is the  CO2 production rate per  m2 body 
surface, BSA is the body surface area (in  m2), MM = 166 is 
the molecular mass of the test drug 13C-methacetin and BW 
denotes the body weight. BSA was computed by the formula 




 , where H is the 
height [in m] of the subject (Haycock et al. 1978).
The data of the LiMAx test were also analyzed by means 
of the reduced compartment model (represented by the non-
shaded part in the reaction scheme shown in Fig. 2) in which 
the kinetic parameters for the exchange of  CO2/bicarbonate 
with body compartments were not included (see Fig. 1).
Targeted multiple reaction monitoring (MRM) 
of methacetine and acetaminophene in the plasma
Pure metabolites were dissolved to a final concentration of 
1 μM in MeOH and 0.1% formic acid, and injected by a 
syringe (7 μL/min) into the triple quadrupole hybrid ion trap 
mass spectrometer (QTrap 6500, Sciex, Framingham, MA). 
Precursor ions were fragmented in positive and negative 
electrospray ionization (ESI) modes, and the most intense 
fragment peaks were chosen and optimized for the following 
parameters: declustering potential (DP) for precursor ions, 
collision energy (CE), and collision cell exit potential (CXP) 
for fragment ions. Transitions were monitored and acquired 
at unit resolution (peak width at 50% was 0.7 ± 0.1 Da toler-
ance) in quadrupole Q1 and Q3. Metabolites were separated 
on a Reprosil-PUR C18-AQ (1.9 μm, 120 Å, 150 × 2 mm ID; 
(1)
LiMAx =
DOBmax × R(PDB) × P × BSA × MM
BW
,
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Dr. Maisch; Ammerbuch, Germany) column at a controlled 
temperature of 30 °C, the four best transitions were chosen 
and all MRM instrument settings are given in Table 1.
For the standard curve, 50  μl of plasma was mixed 
with 20  μl of a dilution series of acetaminophen (par-
acetamol) and methacetin of following concentrations 
(800 nM, 200 nM, 50 nM, 12.5 nM, 3.125 nM, 781.25 pM, 
195.31 pM, 48.83 pM, 12.21 pM, 3.05 pM) and 20 μl of 
internal standard. 180 μL of acetonitrile was added to pre-
cipitate plasma proteins, vortexed for 20 s and incubated 
at room temperature for 10 min. Thereafter, the mixture 
was centrifuged for at 16,000 rcf for 10 min. 100 μL of the 
supernatant was taken and mixed with 44.4 μL of HPLC 
grade water. 5 μL of the mixture was finally injected into 
the LC–MS system. The standard curve was re-measured 
after the acquisition of two complete time series. The stand-
ard curve was acquired interlaced with the measurement of 
samples.
Blood samples were handled as described above with the 
following modification: 50 μL of plasma was mixed with 
Fig. 1  Schematic representation 
of the procedures of the 2DOB 
test and the LiMAx test
Table 1  Statistical measures 
of the predictive power of the 
LiMAx test and parameters of 
the 2DOB test
The classification of the individual subjects in given in Supplementary Table 1
LiMAx kL ML 2DOB score
kL ML
Classifier threshold value 363 2.93E−02 61 5.16E−02 61
True positive rate (TP) 0.75 0.75 0.94 0.94
False positive rate (FP) 0.18 0.14 0.32 0.09
True negative rate (TN) 0.82 0.86 0.68 0.91
False negative rate (FN) 0.25 0.25 0.06 0.06
Positive predictive value (PPV) 0.75 0.80 0.68 0.88
Negative predictive value (NPV) 0.82 0.83 0.94 0.95
Area under the ROC curve (AUC) 0.82 0.85 0.81 0.92
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20 μL of internal standard and 20 μL of HPLC grade water. 
Each sample was injected in triplicates.
The samples (5 µL) were injected and compounds were 
separated on a LC instrument (1290 series UHPLC; Agi-
lent, Santa Clara, CA), coupled online to a triple quadru-
pole hybrid ion trap mass spectrometer QTrap 6500 (Sciex). 
Data acquisition was performed with an ion spray voltage of 
5.5 kV in the positive mode for the electro spray ionization 
source, nitrogen as the collision gas was set to medium, the 
curtain gas was at 30 psi, the ion source gas 1 and 2 was at 
50 and 70 psi, respectively. The interface heater temperature 
was set to 350 °C.
The LC buffer compositions were as follows: (A) 10 mM 
ammonium acetate in LC–MS grade  H2O (adjusted with ace-
tic acid to pH 3.5), (B) LC–MS grade acetonitrile with 0.1% 
formic acid. The 10 min gradient was set as follows: 2% B 
at minutes 0–1, linearly increasing to 45% until minute 5, 
98% between minutes 6 and 7, and again equilibrated at 2% 
between minutes 7.1–10.
Metabolite identification was based on three levels: (i) the 
correct retention time, (ii) four transitions, (iii) and match-
ing MRM ion ratios of tuned pure metabolites as described 
previously (Lau and Ahmad 2013). Peak integration was 
performed using MultiQuantTM software v.2.1.1 (Sciex). 
All peaks were reviewed manually and adjusted if necessary. 
The peak area of the first transition per metabolite was used 
for subsequent calculations. Peak integrations were reviewed 
manually. An internal standard (13C915N l-phenylalanine) 
was used to normalize all LC–MS runs for instrumental 
variations. For the calculation of absolute concentrations, 
the averaged intensities of three replicates (samples and 
standard curve) and the two nearest values of the standard 
curve were taken and calculated as a linear interpolation of 
values on a log–log plot.
Compartment modeling of systemic 13CO2 
and 13C‑methacetin kinetics
We used the compartment model shown in Fig. 2 to describe 
the kinetics of 13C-methacetin (abbreviated with 13M) and 
the additionally formed  H13CO3 + 13CO2 (abbreviated with 
Δ13C) resulting from the administration of 13C-labeled bicar-
bonate and enzymatic conversion of 13C-methacetin. Com-
bining 13CO2 and  H13CO3 into one variable is backed up by 
the fact that both entities are in quasi-equilibrium due to the 
fast reaction catalyzed by the enzyme carboanhydrase. The 
model takes into account the exchange of 13CO2 + H13CO3 
and 13C-methacetin between the blood and other body com-
partments (denoted with X and Y, respectively). Earlier stud-
ies of Barstow et al. (1985, 1990) and Irving et al. (1983) 
on the 13C-bicarbonate kinetics in humans have provided 
evidence for the existence of at least three  CO2 exchange 
compartments differing in the characteristic time constants 
for the exchange kinetics. Over shorter time ranges of about 
15–30 min as considered in our test, the error made by 
neglecting the slow exchange processes should remain suf-
ficiently small.
The reaction scheme shown in Fig. 2 differs from the 
reaction scheme used in our previous work (Holzhutter et al. 
2013) in the following items: (i) the reversible exchange of 
the drug with non-hepatic compartments is now taken into 
account, (ii) the kinetics of the reaction product acetami-
nophen is not considered in the model as the plasma con-
centration of this drug was not monitored, (iii) exchange 
of 13C-methacetin with the liver, conversion to the reaction 
products acetaminophen and 13CO2 and release of the formed 
13CO2 into the blood plasma are lumped together into a sin-
gle process with rate constant kL. The latter simplification 
was necessary as the reversible exchange of 13C-methacetin 
with the liver and with extra-hepatic organs cannot be dis-
cerned in the shape and magnitude of the DOB curve. Note 
that the parameter  kR represents the total elimination rate 
of methacetin from the plasma, including the release of the 
drug from the plasma into the breath as well as other modes 
of irreversible loss as, for example, renal excretion and slow 
covalent fixation in organic molecules.
Kinetic equations
The reaction scheme shown in Fig. 1 is governed by the fol-
lowing set of ordinary differential equations:
Fig. 2  Scheme of the compartment model. The variable Δ13C 
denotes the sum of additionally (above baseline!) formed 13CO2 
and  H13CO3, 13M denotes 13C-methacetin. Both metabolites can be 
exchanged between the plasma and other body compartments lumped 
together into single compartments (X and Y, respectively). Uptake 
of 13C-methacetin into the liver, conversion to the reaction products 
acetaminophen and 13CO2 by CYP1A2, and release of the enzymati-
cally formed 13CO2 into the blood plasma are described by an over-
all reaction with rate constant kL. Phase 1 start with the intravenous 
administration von 13C-labeled bicarbonate. Phase 2 starts about 
30  min later with the intravenous administration von 13C-labeled 
methacetin (see test protocols)
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For the meaning of the rate constants in equation system 




Y represent effective concentrations in the compartments 
X and Y that are related to the true concentrations CX and  MY 














 with Ω denot-
ing the (unknown) volume of the respective compartment. For 
the numerical integration of equation system (2) and estima-
tion of numerical parameter see the Supplementary Informa-
tion (Computational Details).
Definition of a scoring function 
for the quantification of hepatic detoxification 
capacity
Different combinations of model parameters were tried to 
define an appropriate scoring function that reliably quantifies 
the hepatic detoxification capacity. The power of a scoring 
function to discriminate between the detoxification capacities 
of healthy and diseased livers was evaluated by means of a 
ROC (receiver operator characteristic) curve analysis. The area 
under the ROC curve (AUC) is an effective and widely used 
method for evaluating the discriminating power of a diagnostic 
test or statistical model. Threshold values of model parameters 
used in the scoring function were chosen such that the Youden 
index, Y = TP (1-FP)–1 (TP—true positive rate = fraction of 
ill subjects correctly classified, FP—false positive rate = frac-
tion of healthy subjects falsely classified) becomes maximum. 
Assessment of the statistical significance of the difference 
between any two classifiers based on the AUC was performed 
by a non-parametric test that accounts for the correlation of the 
ROC curves (Vergara et al. 2008). Sensitivity of classification 
results against random variations of the training set of healthy 
and diseased subjects was checked by means of Bootstrap resa-
mpling (Mossman 1995) based synthetic data sets created by 













































Adjustment of the compartment model to measured 
DOB data
Both variants of the methacetin breath test, the conven-
tional LiMAx test initiated by the injection of the test drug 
and subsequent monitoring of 13CO2 in the breath, and the 
proposed novel 2DOB test were carried out in 38 subjects 
(for test procedures see Fig. 1). Figure 3 shows typical 
DOB curves of 2DOB test obtained in a liver-healthy sub-
ject and a patient with liver cirrhosis. Experimental and 
computed DOB curves of all subjects are given in Fig. 1 
of the Supplementary Information.
The DOB curve data were used to parameterize the 
compartmental model, i.e. to estimate numerical values for 
the model parameters (see Supplementary Information). 
Model fitting yielded numerical estimates for the rate con-
stants k+C, k−C of Δ13C exchange with body compartment 
X, the rate constant kR of irreversible Δ13C elimination, 
the rate constants  k+M, k−M of 13M exchange with body 
compartment Y and the rate constant kL for the hepatic 
detoxification of 13M. The two-step procedure applied 
for fitting subsets of model parameters separately to the 
first and second phase of the DOB curve was chosen as 
some parameters have a partially redundant influence on 
the height and shape of the DOB curve. For example, an 
increase of DOB values can be elicited by an increase of 
kL or a decrease of the  CO2 elimination rate kR. The sensi-
tivity analysis in the Supplement “Computational Details” 
illustrates that estimation of numerical parameter values 
from different parts of the 2DOB curve is necessary for 
unequivocal estimates of the parameters  k+M and k−M.
From the DOB data of the LiMAX test, only for the 
four model parameters, kR, k+M,  k−M and kL, numerical 
estimates could be derived from the data. Supplementary 
Table 1 depicts for each subject the numerical values of 
all model parameters.
Once parameterized, the model allows simulating the 
time course of Δ13C and 13M in the compartments X and 
Y, respectively. An example is shown in Fig. 3. Compared 
with the healthy subject (HS), the patient with cirrhosis 
(DS) displays a higher uptake rate of Δ13C into body com-
partment X after administration of an identical bolus of 
13C-bicarbonate. Nevertheless, the rise of Δ13C in com-
partment X of DS is lower owing to the significantly lower 
detoxification rate of 13M and correspondingly lower 
liberation rate of Δ13C into the plasma (mirrored by the 
lower maximum of the DOB curve). Note that 40 min after 
administration of the test drug, a substantial portion of 
Δ13C is still retained in body compartment X. The model 
simulation predicts a faster decline of plasma 13 M in HS 
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compared with DS. This is a consequence of DS having 
both a lower detoxification rate of 13M and a lower uptake 
rate of 13M into compartment Y (Fig. 2d, e). We validated 
the model predictions by the good concordance between 
the theoretical curves and measurements of 13M at various 
time points after 13M administration (Fig. 2b). It has to be 
mentioned that for subjects with very low values of the 
detoxification rate constant kL, there was a tendency of the 
computed time course of plasma methacetin to underesti-
mate the true (= experimentally determined) clearance of 
13M from the plasma (see Fig. 2, Supplementary Informa-
tion). This discrepancy is due to the fact that with decreas-
ing rise of the DOB curve after 13M administration, the 
two parameters k+M and k−M for the exchange of 13C-meth-
acetion with compartment Y become less identifiable from 
the DOB curve (see Supplement “Computational details”, 
Parameter Identifiability). At the extreme, if there is no 
rise of the DOB curve at all, indicating that detoxification 
of the drug is absent (kL = 0), the numerical values of  k+M 
and k−M cannot be determined as the reversible exchange 
of 13C-methacetin with compartment Y is not connected 
with the 13CO2 kinetics.
Influence of systemic  CO2 kinetics
The values of the model parameters k+C, k−C and kR derived 
from the first part of the DOB curve provide information on 
the systemic  CO2/HCO3 kinetics of the subject. The numeri-
cal estimates for the Δ13C elimination rate kR varied between 
0.085 and 0.40/min, the mean value across the 38 subjects 
amounts to 0.22/min. For a subject with a normal acid–base 
status of 25 mM plasma  CO2 and a blood volume of 5 L, this 
translates into an average diurnal elimination rate of about 
38 mol/day. This value is above the known resting value of 
about 20 mol/day for the respiratory  CO2 elimination rate 
(Jonderko et al. 2008). Hence, on the average, about one-half 
of the eliminated Δ13C must be rapidly taken up by a “fast” 
body compartment in a quasi-irreversible manner such that 
Fig. 3  Patient-specific kinetics of 13C-labeled  CO2 and methacetin in 
a healthy subject (HS) and a subject with liver cirrhosis (DS). a DOB 
curve data of HS (open circles, green line) and DS (filled circles, red 
line). The lines represent theoretical data obtained by fitting the com-
partment model to the measured DOB data. Over the full time course 
of the experiment, the DOB values were monitored every 25 s. After 
a calibration phase of about 600  s, at time "0" a dose of 2  mg/kg 
body weight of 13C-bicarbonate was injected intravenously. At time 
point TM (indicated by the arrow), a dose of 2 mg/kg body weight of 13C-methacetin was injected intravenously. b Simulated and measured 
time course of plasma methacetin of the normal subject (green curve, 
open circles) and the patient with liver cirrhosis (red curve, closed 
circles). c Simulated time course of additionally formed 13C-CO2/
bicarbonate (Δ13CX*) in body compartment X. Note that relative con-
centrations are shown which are linearly related to the true concen-
trations by a scaling factor that depends on the unknown volume of 
compartment X. d Simulated time course of 13C-methacetin (13 MY*) 
in body compartment Y. Note that relative concentrations are shown 
which are linearly related to the true concentrations by a scaling fac-
tor that depends on the unknown volume of compartment Y. e Flux 
changes in DS compared to HS. Bold arrow: increased flux, dotted 
arrow: decreased flux
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the slow return of this fraction to the plasma is not observ-
able within the time span of the test. This is also reflected 
in an average 13CO2 recovery rate of 54% in the exhaled 
breath at T = 15 min after 13C-bicarbonate administration 
(for individual recovery rates see Fig. 4, Supplementary 
Information).
Notably, the distribution of values for the  CO2 elimination 
rate kR in the group of patients with a liver disease exhibits 
a general shift towards small values (see Fig. 3, Supplemen-
tary Information). Six liver patients had kL values smaller 
than 0.17 min−1 (≈ 66% of the mean). Nevertheless, there 
was no statistically significant difference between the mean 
kL values in the group of healthy subjects (0.222/min) and 
diseased subjects (0.220/min) according to the two-sample 
t test (p = 0.77 at α = 0.05).
Figure 4 illustrates how individual variations of the sys-
temic  CO2 kinetics may influence the shape of the DOB 
curve at fixed 13C-methacetin kinetics. The curves were sim-
ulated with fixed values of the kinetic parameters kL, k+M, 
k−M determining the methacetin kinetics, but varying values 
of the kinetic parameter k+C, k−C, kR obtained for the 38 sub-
jects of this study. The resulting curves differ substantially 
in characteristic curve parameters such as peak value, time-
to-peak value, area under the curve and steepness of decline. 
For subject #33 with normal liver function, the peak values 
of the DOB curves (see Fig. 4a) may differ from the "true" 
peak value by more than a factor of 2. Extreme DOB curves 
would be produced if subject #33 had the  CO2 kinetics of 
subject #23 (maximal positive deviation) or subject #28 
(maximal negative deviation). The coefficient of variation 
(CV = standard deviation/mean) of peak values is 0.25. For 
subject #37 with liver cirrhosis taken as reference, the spread 
of DOB curves is generally lower than for the normal subject 
(CV of peak values = 0.14). For the majority of DOB curves, 
the peak values at T = 300 s. differ less than a factor of 1.5 
from the reference curve.
This suggests that the likelihood of overestimating the 
true drug-detoxifying capacity owing to variations of the 
 CO2 kinetics is lower for a subject with a functionally 
impaired liver. The higher risk of over- or underestimating 
the ’true’ hepatic detoxification capacity in subjects with 
normal or slightly impaired liver functionality compared 
with subjects with severe liver dysfunction is also reflected 
in the relationship between the detoxification rate constant 
kL and the parameter LiMAx serving as predictor of the 
detoxification capacity in the conventional LiMAx test and 
representing up to a scaling factor the peak value of the DOB 
curve (see Fig. 5). Despite the highly significant overall cor-
relation of these two parameters, the largest deviations from 
the hyperbolic regression line occur in the middle range of 
 kL values (grey-shaded area in Fig. 5) indicating either nor-
mal or mildly impaired detoxification capacity.
The predictive capacity of model parameters 
as disease classifiers
Next we studied the suitability of model parameters for the 
binary classification of the subjects liver into normal (disease 
class "1") or impaired (disease class "2"). Obviously, the 
model parameter kL quantifying the hepatic detoxification 
Fig. 4  Simulated DOB curves at fixed methacetin kinetics, but vari-
able  CO2 kinetics. a The kinetic parameters determining the meth-
acetin kinetics were fixed at those values obtained for subject #33 
with normal liver function: kL = 0.039  min−1, k+M  = 0.036  min−1, 
k−M  = 0.082  min−1. b The kinetic parameters determining the 
methacetin kinetics were fixed at those values obtained for sub-
ject #37 with liver cirrhosis: kL  = 0.010 min−1, k+M  = 0.131 min−1, 
k−M  = 0.06 min−1. The set of parameters, k+C, k−C, kR, determining 
the  CO2 kinetics were put to the values obtained for the 38 subjects, 
i.e. each curve represents the DOB curve of a subject comprising the 
methacetin kinetics of subject #9 (a) or subject #37 (b) but the  CO2 
kinetics of one of the subjects 1–38. Note that the curves represent 
the second part of the 2DOB curves starting with the administration 
of 13C-methacetin, i.e. time "0" corresponds to time Tm of the full 
test curve. For a better comparison of curves, the residual DOB value 
at t =  Tm was subtracted so that the initial DOB values at time = 0 is 
zero for all curves. Blue curves: true DOB curve of the reference sub-
ject (subject #33 in A, subject #37 in b). Coefficient of variation (CV) 
of maximum DOB values: = 0.25 (a), 0.14 (b)
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rate of the test drug should serve as an appropriate clas-
sifier. Testing the predictive capacity of kL by means of a 
receiver operating characteristics (ROC) yielded a value of 
AUC = 0.85 for the area under the curve (AUC), a true posi-
tive rate (TP) of 0.75 and a true negative rate (TN) of 0.86. 
Thus, the predictive power achieved with the parameter kL 
was not better than the predictive power of the LiMAx score 
(AUC = 0.82, TP = 0.75, TN = 0.86). Notably, both kL and 
the LiMAx yielded false negative classifications for the same 
group of subjects. This liver suggests that a chronic liver 
disease must not be necessarily paralleled by a significantly 
lowered chemical conversion rate of the test drug.
We then tested whether other model parameters may 
serve as possible disease predictors. Intriguingly, parameters 
k−M describing the initial rate of methacetin uptake into the 
storage compartment Y yielded a surprisingly high qual-
ity of disease classification (AUC = 0.72). Parameter k+M 
describing the release rate of methacetin from compartment 
Y also yielded a statistically significant classification with 
AUC = 0.65. Hence the storage capacity of compartment Y 
for methacetin appears to be reduced in diseased livers. As 
the storage capacity of compartment Y depends on both k+M 
and k−M, we used the average concentration of methacetin 
stored in compartment Y over a time span TS = 3000 s. after 
administration of 13M at time t = TM, (see Fig. 6)
as a new disease classifier yielding an AUC value of 0.81. 












reached already a true positive rate of more than 90% at a 
false positive rate of about 30%, i.e.  ML is predestined more 
than all other measures tested to reliably identify patients 
with liver disease.
We then examined whether a combination of the two 
disease predictors, kL and  ML, may provide an even better 
classification than either parameter alone. As there are end-
less possibilities to combine the model parameters into a 
scoring function, we followed Occam’s razor command “not 
to multiply entities without necessity” (Schaffer 2015) and 
used the most simple (linear) combination of the tw model 
parameters kL and  ML that individually provided the best 
classification results:
The 2DOB score defined in Eq. (4) is a continuous meas-
ure of the hepatic detoxifications capacity, whereby values 
smaller than unity indicate an impaired liver function. The 
2DOB score is basically identical with the detoxification rate 
kL except for those cases where kL remains below the thresh-
old value kLc (indicating an impaired detoxification rate) 
whereas the storage capacity  ML is larger than the threshold 
value  MLc. This definition of the 2DOB score implicates 
that the liver is classified as impaired if and only if both 
parameters, kL and  ML, are smaller than the cut-off values 
kLc and  MLc (see Fig. 7).
With the 2DOB score used as classifier, indeed a signifi-















Fig. 5  LiMAx versus model parameter kL (detoxification rate). 
LiMAx values were determined from the DOB curves of the conven-
tional LiMAx test according to Eq. (1) (data given in Supplementary 
Table 1). Green and red dotes indicate data for controls and patients. 
The grey-shaded region highlights the range of largest deviations 
between kL and LiMAx. The dotted curve represents the best-fit 
hyperbolic relationship between LIMAX and kL: LIMAX = 744 × kL/
(0.028 + kL)
Fig. 6  Receiver operating characteristic to assess the predictive power 
of the 2DOD and LiMAx test. Black curve: LiMAx value used a 
classifier (AUC = 0.82). Blue curve: parameter kL used as classifier 
(AUC = 0.83). Green curve: parameter  ML defined by equn (5) used 
as classifier (AUC = 0.81). Red curve: 2DOB score defined by equn 
(6) used as classifier (AUC = 0.95)
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the AUC 2DOBscore = 0.95 is significantly larger than the AUC 
LiMAx = 0.82 (z = 1.9, p = 0.028).
The cut-off values kLc and  MLc given in Table 1 were 
determined by maximizing the AUC value across the 
group of 38 subjects.
Relationship between the 2DOB score and the MELD 
score
As the 2DOB score is defined as a continuous measure 
of the hepatic detoxifications capacity, it was tempting to 
check whether the 2DOB score correlates with clinically 
applied parameters that are used in the clinics for assessing 
the severity of chronic liver diseases. Figure 8 reveals a 
high correlation between the 2DOB score and the MELD 
(Model for End-Stage Liver Diseases) core of the 38 test 
subjects (RSpearman = 0.92, p < 0.00001).
There exists a clear monotone and highly non-linear 
relationship between the 2DOB score and the MELD 
score. 2DOB scores smaller than 0.4 are consistently asso-
ciated with MELD scores larger than 8. The only outlier 
occurred for subject #33 (black data point in Fig. 8) who 
has a clinically inconspicuous liver, correctly reflected by 
a 2DOB score > 1, but an ordinarily high MELD score of 
14 due to the fact that this subject was under steady treat-
ment with anticoagulants which are known to influence 
the MELD score. As shown in Fig. 8, the 2DOB score 
proves as a much more sensitive indicator of a beginning 
or moderate liver disease than the MELD score. That is 
no surprise as the MELD was developed and adapted as a 
prognostic tool in advanced liver diseases (Lau and Ahmad 
2013).
Robustness of the 2DOB test and further test 
optimization
Age‑differences between controls and patients
The subjects in the control group of our study were sig-
nificantly younger (mean age = 42.4 years) than the subjects 
with liver disease (mean age = 55.1 years). Aging has been 
Fig. 7  2DOB score as function 
of the normalized (parameters 
kL and ML. Parameters are 
normalized with respect to their 
cut-off values, i.e. kL/kLC ≥  1 
means kL  ≥ kLC. The red lines 
enclose the region of score val-
ues that are smaller than unity 
thus indicating an impaired 
hepatic detoxification capacity. 
Note that according to definition 
(6) of the 2DOB score, small 
values of the detoxification rate 
kL below the threshold kLC yield 
nevertheless a 2DOB score 
larger than 1 (= liver healthy) if 
the value of the storage capac-
ity exceed the threshold value 
(ML ≥ MLc)
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Fig. 8  Relationship between the 2DOB score and the MELD score of 
the 38 test subjects. Green dots: normal subjects. Red dots: subjects 
with clinically diagnosed liver disease. The black line is intended to 
guide the eye and to underline the non-linear relationship. The verti-
cal blue lines at 2DOB score = 1 mark the threshold between normal 
and impaired detoxification capacity
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reported to cause moderate declines in the Phase I metabo-
lism of certain drugs (Cieslak et al. 2016; Schmucker 2005; 
Schmucker and Wang 1980) and thus could have affected the 
classifications. Therefore, we split the group of the 22 con-
trol subjects into 2 sub-groups, comprising 11 healthy sub-
jects aged from 22 to 49 (mean age = 30.7) and 11 healthy 
subjects aged from 50 to 59 (mean age = 54.5). The older 
control group matches approximately the age of the diseased 
subjects. There was a slight albeit statistically insignificant 
tendency towards higher LiMAx scores (from 428 to 458) 
and kL values (from 0.044 to 0.054), suggesting a marginal 
age-related increase of CYP1A2-dependent metabolization 
rates in normal livers. Interestingly, the mean value of the 
parameter  ML dropped from 62.5 in the group of younger 
controls to 50.7 in the group of older controls, suggesting an 
age-dependent decline of the storage capacity of the liver-
associated compartment Y.
The classifications performed using the two age-corrected 
control groups separately (see Table 3, Supplementary Infor-
mation), yielded identical statistical measures for the 2DOB 
test. Of note, the cut-off values for kL and  ML were identical 
irrespective of the control group used. Changes in the ROC 
statistics of the LiMAx test were also very little affected by 
the choice of the control group. However, the cut-off value 
separating normal and diseased livers was significantly 
affected (282 versus 363) when using either the younger or 
older controls as reference.
We also tested the robustness of LiMAx- and 2DOB-
based classifications against random variations of the train-
ing set of healthy and diseased subjects using the method 
of Bootstrap resampling (Mossman 1995). The frequency 
distribution of AUC values shown in Fig. 9 was constructed 
by choosing randomly with replacing 38 subjects from the 
original set, i.e. the randomly sampled set contained some 
data sets more than once (overrepresented) but some data 
sets were missing. For this synthetic data set, values of AUC 
and the cut-off parameters were computed. This resampling 
was applied 1000 times. The Bootstrap variance of AUC and 
of the cut-off values are also given in the legend to Fig. 9. 
In less than 2% of trials, the AUC 2DOB was below 0.8, the 
mean AUC 2DOB was 0.94.
Regarding the safety and operational feasibility of the test 
protocol, there were no complications with any participant. 
Nevertheless, to keep the time interval for the investigation 
as short as possible, we checked whether the duration of the 
test can be reduced to about 30 min in total. To this end, 
we used only a part of the DOB data recorded for 15 min 
after administration of 13C-bicarbonate and for 15 min after 
administration of 13C-methacetin for the adjustment of the 
compartment model and estimation of kinetic parameters. 
With the short-time 2DOBtest, the 2DOB score yielded 
almost the same classification quality for the group of 38 
subjects (AUC = 0.94, 4 misclassifications). The results of 
the 15 min test are given in Supplementary Table 1.
Discussion
The need for non‑invasive tests capable of detecting 
early‑stage liver diseases
One of the main difficulties with liver diseases is that 
patients often do not present symptoms or signs until the 
disease becomes advanced. Around 50% of patients receive 
their first diagnosis when they arrive in accident and emer-
gency units, typically in their 40 s or 50 s, with jaundice, 
gastrointestinal bleeding, abdominal swelling and disorien-
tation. Detection of ongoing liver diseases at an early stage 
is required to prevent or reduce further disease progression 
by lifestyle changes and pharmacological treatment. Non-
invasive diagnostic techniques currently used are serum bio-
markers and transient elastography (TE). However, serum 
Fig. 9  Variability of AUC values for the 2DOB and the LiMAXx. Variability was assessed by Bootstrap resampling (1000 trials). Green-shaded 
bars: LiMAx. White bars: 2DOB score
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biomarkers are not liver specific and TE results require an 
expert clinician for interpretation (European Association 
for Study of Liver and Asociacion Latinoamericana para el 
Estudio del Higado 2015). Regarding the use of breath tests 
for the detection of liver diseases, the elevation in the breath 
of naturally occurring volatile biomarkers such as limonene, 
methanol and 2-pentanone has been reported to reliably 
identify patients liver cirrhosis (Fernandez Del Rio et al. 
2015).  The same quality of discrimination between healthy 
and cirrhotic livers has been achieved with the LiMAx test 
(Buechter et al. 2018). However, differentiating between 
patients with and without cirrhosis alone has limited value, 
as this can be performed reliably with routine clinical meth-
ods. It is still a challenge to establish non-invasive liver func-
tions tests that are sensitive and specific enough to detect the 
early onset of restrictions in the metabolic capacity of the 
liver. Taking for granted that the metabolization of drugs is 
a reliable indicator for the functional capacity of the liver 
as a whole, functional breath tests such as the LiMAx are 
promising test candidates provided that major confounding 
factors can be eliminated.
Exhaled 13CO2 as reliable indicator of hepatic 
detoxification capacity
Using the kinetics of exhaled 13CO2 produced during hepatic 
metabolization of a labeled test compound as indicator of 
the liver’s detoxification capacity inevitably raises the prob-
lem to what extend this signal is influenced by the systemic 
distribution of  CO2. Measuring the rate of  CO2 respiration 
doesn’t really solve this problem as this measure does not 
capture the exchange of plasma  CO2 with other body com-
partments. Therefore, we designed a test variant that allows 
to assess how a defined bolus of 13CO2 is eliminated from 
the plasma of the patient and to exploit this information for 
a more reliable assessment of the drug detoxification rate. To 
this end, we used a fit-for-purpose compartment model that 
condenses the numerous physiological processes involved 
in the hepatic uptake and metabolization of the drug and 
the systemic distribution of  CO2 into a manageable number 
of phenomenological parameters. The model provided an 
excellent fit to measured DOB curve data of all 38 subjects 
included in this study (see Fig. 1, Supplementary Informa-
tion). Based on the high variability of the individual kinetic 
parameters for systemic  CO2 kinetics (illustrated in Fig. 4), 
one may expect variations in the maximum of the DOB 
curve by a factor of 2 for normal subjects and a factor of 1.5 
for subjects with restricted detoxification capacity.
The direct evaluation of the capability of the novel 2DOB 
breath test to provide reliable estimates of the hepatic drug 
detoxification rate would ultimately require measurements 
of arteriovenous drug concentration differences across the 
patient’s liver. As this has to be excluded for obvious reasons, 
an indirect evaluation may consist in testing the capability 
of the 2DOB test to correctly discriminate between liver 
healthy and clinically diagnosed liver-diseased subjects. 
Taking into account the patient-specific  CO2 kinetics in the 
estimation of the hepatic conversion rate of 13C-methacetin 
(parameter kL) provided a modest improvement of the dis-
crimination between normal versus impaired detoxification 
capacity compared with the conventional LiMAx test. This 
is plausible because the likelihood that the "true" maximum 
of the DOB curve (the basis for the definition of the LiMAx 
score) of patients with severe liver dysfunction is falsely 
shifted up to values within the normal range just due to an 
extreme  CO2 kinetics remains small: The coefficient of vari-
ation for the exemplary case shown in Fig. 4b was 0.14. The 
same holds for the likelihood of a strong down shift of the 
DOB maximum for subjects with high detoxification capac-
ity. However, for patients with detoxification capacities close 
to the borderline between normal and mild metabolic dys-
function, the correction of DOB values for the influence of 
the individual  CO2 kinetics may be relevant. 7 out of 8 the 
cases misclassified by the LiMAx, but correctly classified 
by the 2DOB parameter  kL are just in the middle range of kL 
and LiMAx values (see grey-shaded region if Fig. 5) where 
a marginal shift in the maximum of the DOB curve may turn 
the classification result into the opposite.
In summary, the already well-established LiMAx score 
appears to be robust against the bias caused by the systemic 
 CO2 kinetics in subjects comprising either normal or drasti-
cally reduced hepatic detoxification capacities. However, in 
subjects with borderline capacities, the 2DOB test promises 
a significant improvement of the classification quality.
Plasma clearance of methacetin = metabolization 
and temporary storage
Generally, owing to its chemical similarity with acetami-
nophen, methacetin should rapidly and evenly distribute 
throughout most tissues and fluids as reported for aceta-
minophen (Forrest et al. 1982). Therefore, it is difficult to 
specify the volume of model compartment Y to convert the 
apparent rate constants into true rate constants. An intrigu-
ing finding of our study was that a substantial part of the 
test drug should be transiently stored in a body compart-
ment that is closely associated with the liver. Distinction 
between two modes of plasma clearance of methacetin, 
reversible storage (without detoxification) and detoxifica-
tion, was possible because the reversible exchange of the 
drug with the storage compartment influences the shape 
of the declining part of the DOB curve (see sensitivity 
analysis in Fig. 5 of the Supplementary Information). The 
decline of the DOB curve is influenced by both the uptake 
of 13CO2 from the plasma into other body and the uptake 
of 13C-methacetin into the exchange compartments. Hence, 
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the share of the  CO2 kinetics in the shape of the declining 
part of the DOB curve has to be known to estimate reliable 
values for the relevant parameters, k+M and k−M, determin-
ing the magnitude of the parameter  ML. An issue with the 
correct estimation of  ML occurs if the DOB curve is very 
flat, i.e. for livers with very low detoxification capacity kL 
(see Fig. 3b). Fortunately this is no impact on the 2DOB 
score because for very small values of kL the estimated 
value of  ML is also small, i.e.  ML<<  MLc, so that the 
2DOB score is identical with kL and the liver is classified 
as functionally impaired.
The physiological and anatomical nature of methacetin-
storing body compartments which we condensed into the 
single model compartment Y remains elusive. Owing to 
the chemical similarity of methacetin with acetaminophen 
(APAP) we searched the literature for known facts about the 
pharmacokinetics of APAP. A recently published compart-
ment model of APAP clearance from the plasma worked 
well without introducing a reversible exchange of APAP 
(Mian et al. 2019). Reversible binding of acetaminophen to 
plasma proteins like albumin (the plasma level of which can 
be reduced in severe liver failure) can be excluded as this is 
a very rapid process in contrast to the rather slow uptake and 
release according to our modeling data. With an association 
rate constant of about 5.8 × 104/M/s as determined for bind-
ing of tryptophane to albumin (Talbert et al. 2002) and an 
average albumin plasma concentration of 40 g/l = 600 μM, 
the apparent first-order rate constant for drug binding would 
be about 2000/s which is about five orders of magnitude 
larger than typical values of the model parameter k−M. Thus, 
it is tempting to assume that compartment Y is identical 
with the liver itself, whereby the transient storage without 
chemical conversion is either confined to a special fraction 
of hepatocytes or occurs in an intra-cellular compartment 
of all hepatocytes. Hepatocytes have cytosolic binding 
proteins (e.g. ligandin) that act as storage compartment for 
drugs and endogenous metabolites. Therefore, with loss of 
hepatocytes, there is loss of storage capacity. This expla-
nation receives support from our observation that the stor-
age capacity  ML was lower in the group of older controls 
compared with the group of younger controls (see section 
“Robustness of the 2DOB test” below), possibly reflecting 
the age-dependent decline of active liver mass (Wakabayashi 
et al. 2002). As binding of the drug to cellular binding pro-
teins will be similarly fast as binding to serum proteins, the 
rate constants for the reversible uptake to and release of 
from hepatocytes should reflect the transport rates across 
the plasma membrane (Austin et al. 2005). The capacity of 
the liver to efficiently remove drugs and other xenobiotics 
from the circulation may also be determined by its capac-
ity to transiently store the drug before it can be chemically 
converted. This may in particular hold in situations when the 
detoxifying enzyme systems become saturated. Testing this 
hypothesis would mean to quantify the arteriovenous dif-
ference of labeled 13C-methacetin and 13CO2 in a laboratory 
animal. Anyway, storage of the test drug without immediate 
chemical conversion in the liver appears to be a mechanism 
that contributes to the rapid clearance of the drug from the 
plasma.
Conclusion
Individual variations in the systemic  CO2 kinetics may 
have a significant influence on the parameters of the DOB 
curve. The novel test variant 2DOB takes this confounding 
effect into account and promises a significant improve-
ment in the assessment of impaired hepatic detoxifica-
tion capacity compared to the well-established LiMAx 
test in cases where the detoxification capacity is at the 
borderline between the normal and moderately reduced 
level. The suitability of the test for the reliable charac-
terization of the natural history of chronic liver diseases 
(fatty liver → fibrosis → cirrhosis) has to be assessed in 
further studies. Validation of the test in an animal model 
would be perfect to remove remaining uncertainties of the 
model-based analysis by direct measurement of hepatic 
CYP activities and concentration profiles of 13CO2 and 
13C-methacetin in different body compartments during the 
long-term progression of a liver disease (e.g. non-alco-
holic fatty liver NAFLD).
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